CO6430497A2 - Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento - Google Patents

Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Info

Publication number
CO6430497A2
CO6430497A2 CO11117849A CO11117849A CO6430497A2 CO 6430497 A2 CO6430497 A2 CO 6430497A2 CO 11117849 A CO11117849 A CO 11117849A CO 11117849 A CO11117849 A CO 11117849A CO 6430497 A2 CO6430497 A2 CO 6430497A2
Authority
CO
Colombia
Prior art keywords
follow
treatment
biomarkers
methyl
additional
Prior art date
Application number
CO11117849A
Other languages
English (en)
Inventor
Tokuzo Arao
Kanae Kudo
Kazuhiko Nakagawa
Nishio Kazuto
Original Assignee
Boheringer Ingelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6430497(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boheringer Ingelheim Internat Gmbh filed Critical Boheringer Ingelheim Internat Gmbh
Publication of CO6430497A2 publication Critical patent/CO6430497A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

La presente invención se refiere a biomarcadores para hacer un seguimiento de la actividad del compuesto 3-Z-[1-(4-(N-((4-metil-piperazin-1-iI)-metilcarbonil)-N-metil-amino)-anilino)-1-feniI-metilen]-6-metoxicarbonil-2-indolinona o una sal farmacéuticamente aceptable del mismo, y especialmente su forma de sal monoetanosulfonato, cuando se usa solo u opcionalmente en combinación con ingredientes farmacéuticamente activos adicionales y/o tratamientos adicionales, tales como, por ejemplo, radioterapia.
CO11117849A 2009-03-12 2011-09-12 Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento CO6430497A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
CO6430497A2 true CO6430497A2 (es) 2012-04-30

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11117849A CO6430497A2 (es) 2009-03-12 2011-09-12 Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Country Status (24)

Country Link
US (1) US8802384B2 (es)
EP (1) EP2406628A1 (es)
JP (1) JP5667581B2 (es)
KR (1) KR20110137307A (es)
CN (1) CN102334030A (es)
AR (1) AR076113A1 (es)
AU (1) AU2010223256B2 (es)
BR (1) BRPI1011688A2 (es)
CA (1) CA2755055A1 (es)
CL (1) CL2011002260A1 (es)
CO (1) CO6430497A2 (es)
EA (1) EA201101300A1 (es)
EC (1) ECSP11011323A (es)
IL (1) IL214747A0 (es)
MA (1) MA33120B1 (es)
MX (1) MX2011009482A (es)
NZ (1) NZ594843A (es)
PE (1) PE20120592A1 (es)
SG (1) SG174324A1 (es)
TN (1) TN2011000457A1 (es)
TW (1) TW201100802A (es)
UA (1) UA107789C2 (es)
UY (1) UY32482A (es)
WO (1) WO2010103058A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2299987T (lt) * 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8557531B2 (en) 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
MX2009002471A (es) * 2006-09-07 2009-03-20 Astrazeneca Ab Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.
JP2010524003A (ja) 2007-04-13 2010-07-15 ブリストル−マイヤーズ スクイブ カンパニー 血管内皮増殖因子受容体−２モジュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer

Also Published As

Publication number Publication date
ECSP11011323A (es) 2011-10-31
CL2011002260A1 (es) 2012-03-23
US20100233705A1 (en) 2010-09-16
KR20110137307A (ko) 2011-12-22
BRPI1011688A2 (pt) 2016-03-22
EA201101300A1 (ru) 2012-04-30
UA107789C2 (en) 2015-02-25
MX2011009482A (es) 2011-09-27
US8802384B2 (en) 2014-08-12
UY32482A (es) 2010-10-29
CA2755055A1 (en) 2010-09-16
JP2012520446A (ja) 2012-09-06
TN2011000457A1 (en) 2013-03-27
WO2010103058A1 (en) 2010-09-16
JP5667581B2 (ja) 2015-02-12
AU2010223256A1 (en) 2011-09-15
AR076113A1 (es) 2011-05-18
TW201100802A (en) 2011-01-01
MA33120B1 (fr) 2012-03-01
IL214747A0 (en) 2011-11-30
CN102334030A (zh) 2012-01-25
EP2406628A1 (en) 2012-01-18
PE20120592A1 (es) 2012-06-09
AU2010223256B2 (en) 2014-08-21
NZ594843A (en) 2014-03-28
SG174324A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
AR080643A1 (es) Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
CO6420359A2 (es) Anticuerpo anti-lectina similar a inmuglobulina de unión a ácido siálico-15
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112012004377A2 (pt) terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
NZ702663A (en) Nuclear transport modulators and uses thereof
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
WO2012176172A3 (en) Combination therapy with psd-95 inhibitor for ischemia
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112012028136A2 (pt) terapia de combinaçao
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112012020629A2 (pt) forma cristalina, e, método para a terapia de um distúrbio
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso

Legal Events

Date Code Title Description
FC Application refused